Sun Pharmaceuticals today reported a consolidated net profit of Rs 881.30 crore for the third quarter (Q3) ended December 31, 2012.
The company had posted a net profit of Rs 668.30 crore in the corresponding period previous fiscal, Sun Pharmaceutical Industries Ltd said in a filing to the BSE.
Consolidated net sales of the company stood at Rs 2,852 crore for the third quarter ended December 31, 2012. It stood at Rs 2,145.13 crore for the same period of 2011-12 fiscal.
"All our businesses continue to perform in-line with our expectations," Sun Pharma Managing Director Dilip Shanghvi said.
The company said the third quarter results were not comparable to the previous year due to the US-based Dusa Pharmaceuticals becoming a subsidiary of the company during December 2012.
The results for the current period include results of Dusa from the date it became subsidiary of Sun Pharma and, therefore, the corresponding figures for the previous period are not comparable, the company said.
Shares of Sun Pharma were trading at Rs 749 apiece on the BSE in the afternoon trade, up 0.03 per cent from its previous close.